Mandate

Vinge has assisted STRAX in connection with a 30 MEUR facilities agreement with Proventus Capital Partners IV as lender

Vinge assisted the STRAX group in refinancing and the entering into a facilities agreement with Proventus Capital Partners IV (“Proventus”) as lender in the total amount of EUR 30 million.

Over the past five years, a banking consortium consisting of four German banks has accounted for the majority of the STRAX group’s long-term financing. The new facilities agreemet was entered into with Proventus in July 2020 and is for a term of five years. The loan was paid out in two tranches, one subordinated tranche of EUR 6 million in July 2020 to provide additional working capital until the full amount was paid out on 30 October 2020, in connection with the refinancing of the maturing loans to the German bank consortium. This was announced by Strax AB 17 July 2020.

STRAX is a market-leading global specialist in mobile accessories. STRAX has two complementary businesses - own brands and distribution (retail and online marketplaces) - where the lifestyle audio brand Urbanista is the flagship along with the licensed brands within Adidas. Today, STRAX has over 200 employees in 12 countries with its operational HQ and logistics center based in Germany. STRAX AB is listed on Nasdaq Stockholm Stock Exchange.

Vinge's team has consisted of Fabian Ekeblad, Henrik Ossborn, Paulina Malmberg and Elin Samara. Jesper Schönbeck advised on capital market issues.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025